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Diabetic kidney disease (DKD) is a major, yet under-
appreciated, contributor to the global burden of disease 
[1]. Globally, an estimated 415 million people lived with 
diabetes in 2015, with the worldwide prevalence of diabe-
tes projected to increase to 642 million in 2040 if current 
trends continue [1]. With an increase in the prevalence of 
diabetes comes an increase in the incidence of DKD. 
While improvements in diabetes management have 
translated to meaningful improvements in many diabe-
tes-related outcomes, its impact upon DKD and the de-
velopment of end-stage renal disease (ESRD) have been 
less robust [2]. In fact, it has been shown that the major-
ity of the excess risk for all-cause and cardiovascular dis-
ease (CVD)-related mortality in people with diabetes is 
related to the presence of DKD [3]. Given the undeniable 
impact of DKD, there are clear health and economic jus-
tifications for improving the outcomes of people living 
with this chronic disease.
The sodium-glucose co-transporter 2 (SGLT-2) inhib-
itor class of medications have received considerable re-
cent attention as related to their impact on CVD and renal 
outcomes – largely driven by findings reported from two 
key cardiovascular outcome trials (CVOTs): The Empa-
gliflozin Cardiovascular Outcomes and Mortality in 
Type  2 Diabetes (EMPA-REG OUTCOME) trial [4, 5] 
and the Canagliflozin Cardiovascular Assessment Study 
( CANVAS) [6]. The EMPA-REG OUTCOME clinical 
trial was the first CVOT performed with an antihypergly-
cemic agent to report statistically significant reductions 
in CVD and renal outcomes [4, 5]. Empaglifozin signifi-
cantly lowered rates of death from CV causes (4 vs. 6%; 
38% relative risk reduction), hospitalization for heart fail-
ure (3 vs. 4%; 35% relative risk reduction), and death from 
any cause (6 vs. 8%; 32% relative risk reduction) in pa-
tients with type 2 diabetes mellitus and baseline CVD [4]. 
Post hoc analyses of the EMPA-REG trial also showed 
beneficial renal effects including a reduction of albumin-
uria, slowing down of estimated glomerular filtration rate 
(eGFR) decline, and a 50% reduction in risk of progress-
ing to ESRD [5]. Similar to EMPA-REG OUTCOME, 
CANVAS reported significantly lower rates for the pri-
mary outcome (composite of death from CV causes, non-
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fatal myocardial infarction, or nonfatal stroke) in partici-
pants receiving canagliflozin versus placebo (HR 0.86, 
95% CI 0.75–0.97; p < 0.001 for noninferiority; p = 0.02 
for superiority) [6]. In regard to renal outcomes, the 
CANVAS investigators noted that on the basis of pre-
specified hypothesis sequence, the designated renal out-
comes reported for the trial were not viewed as statisti-
cally significant [6]. Nonetheless, CANVAS reported 
“possible benefits” of canagliflozin treatment for both 
progression of albuminuria (HR 0.73, 95% CI 0.67–0.79) 
and on the composite renal outcome of a sustained 40% 
reduction in eGFR, the need for renal-replacement ther-
apy, or death from renal causes (HR 0.60, 95% CI 0.47–
0.77). Indeed, these findings with canagliflozin are  further 
supported by a post hoc analysis from the  CANTATA-SU 
trial that showed canagliflozin treatment, when com-
pared to the addition of glimepiride in patients on back-
ground metformin, significantly decreased albuminuria 
and slowed down eGFR decline [7].
While these findings are both promising and exciting, 
and in the case of EMPA-REG OUTCOME, have resulted 
in major changes to clinical treatment recommendations 
from such organizations as the American Diabetes Asso-
ciation, questions still abound regarding the mechanism(s) 
of renal protection, identification of patients most likely 
to benefit from SGLT-2 inhibitor therapy, and the risk/
benefit balance for SGLT-2 inhibitor use in people with 
DKD. While the weight and blood pressure benefits of 
SGLT-2 inhibitors largely persist in patients with DKD 
(at least in patients with stage 3 chronic kidney disease 
[CKD]), the glucose-lowering benefits are diminished 
with a decline in eGFR. For this reason, at least in part, 
current SGLT-2 inhibitor labeling recommends dose re-
ductions based on eGFR, with use not recommended for 
empagliflozin and canagliflozin in patients with an eGFR 
<45 mL/min/1.73 m2, and use of dapagliflozin contrain-
dicated in patients with an eGFR <30 mL/min/1.73 m2 
(Table 1). 
Fortunately, additional work is being done to shed 
more light on such unanswered questions. In this issue of 
the American Journal of Nephrology, Jardine et al. [8] pres-
ent the study rationale and design for the much anticipat-
ed Canagliflozin and Renal Endpoints in Diabetes and Es-
tablished Nephropathy Clinical Evaluation  (CREDENCE) 
study. CREDENCE is a randomized, double-blind, place-
bo-controlled, parallel-group, event-driven multicenter 
study of the effects of canagliflozin, a SGLT-2 inhibitor, on 
renal and cardiovascular outcomes in subjects with type 2 
diabetes mellitus and diabetic nephropathy with eGFRs 
≥30–90 mL/min/1.73 m2 and albuminuria (urinary albu-
min-to-creatinine ratio >300 to ≤5,000 mg/g). The prima-
ry outcome measure for  CREDENCE is a composite end-
point that includes ESRD, doubling of serum creatinine, 
and renal or CV death. Given the paucity of available phar-
macotherapies that ameliorate the decline of DKD, the 
CREDENCE trial has the potential to substantially impact 
the fields of nephrology and endocrinology. As noted by 
Jardine et al. [8],  CREDENCE, due to unique aspects of the 
population enrolled and the design of the study, will pro-
vide important data that will add to the knowledge gained 
from the  CANVAS and EMPA-REG OUTCOME studies. 
Notable unique aspects of the trial include (1) its use of 
CKD-EPI for ascertainment of kidney function; (2) inclu-
sion of patients at the highest risk for kidney disease pro-
gression (proteinuric CKD patients); (3) its prerequisite of 
participants receiving a stable regimen of the maximum 
tolerated dose of an angiotensin-converting enzyme in-
hibitor or angiotensin receptor blocker; (4) and its prima-
Table 1. Dosing recommendations for sodium-glucose co-transporter 2 inhibitor use in diabetic kidney disease
Agent Dosing recommendations based on eGFR, mL/min/1.73 m2
Empagliflozin No dose adjustment required if eGFR ≥45
Avoid use and discontinue in patients with eGFR persistently <45
Canagliflozin No dose adjustment required if eGFR ≥60
100 mg daily if eGFR 45–59
Avoid use and discontinue in patients with eGFR persistently <45
Dapagliflozin Avoid initiating if eGFR <60
Not recommended with eGFR 30–60
Contraindicated with eGFR <30
eGFR, estimated glomerular filtration rate.
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ry composite outcome that incorporates both renal and 
CVD endpoints. In terms of safety analyses, CREDENCE 
will also provide additional insight into the finding of in-
creased amputation risk that was reported in CANVAS 
[6].
Recently reported cardiovascular and renal outcome 
data from agents within the SGLT-2 inhibitor class are 
nothing short of exciting. Additional data from 
 CREDENCE and other pending renal/CVOTs will en-
hance our collective knowledge and begin to inform some 
of the unanswered questions pertaining to SGLT-2 in-
hibitor use in patients with DKD, and will hopefully pro-
pel us closer to “moving the needle” on renal and CVD 
outcomes in the DKD population. 
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